Overview

• The PARTNER trial showed a 100% three-year survival rate for patients receiving chemotherapy and Olaparib before surgery, compared to 88% in the control group.
• Olaparib, a PARP inhibitor targeting BRCA-mutated cancer cells, was administered in a 12-week pre-surgical regimen with a 48-hour gap after chemotherapy to optimize effectiveness.
• Researchers from Addenbrooke's Hospital and the University of Cambridge led the study across 23 NHS sites, enrolling 84 patients in total.
• The trial's findings, published in *Nature Communications*, suggest potential applications for other BRCA-related cancers, including ovarian, prostate, and pancreatic cancers.
• Further larger-scale studies are planned to validate the results, with discussions underway on NHS adoption and potential cost savings compared to current post-surgical treatment protocols.